GO Main Menu Go Main Contents Go Bottom Menu

Celebrating the beginning of the biosimilar era When the biosimilar industry was newly emerging, Celltrion Healthcare established strategic relationship with Celltrion as co-developer with strong conviction that the biosimilar business would be successful. In 2013, Remsima®, the world’s first biosimilar monoclonal antibody, was launched in Europe that led the global pharmaceutical market, bringing the
significance of biosimilars to worldwide attention.

1999~2009 history image
1999.12
Established Nexol Inc
2008.08
Established Global distribution agreement
with Celltrion
2012~2013 history image
2009.03
Changed the company name to Celltrion
Healthcare
2013.09
Launched Remsima® in Europe

Proving the potential success of biosimilars The total cumulative export value of Remsima® reached KRW 1 trillion in 2016, which was a great achievement in the
biopharmaceutical history of Korea. In addition, Celltrion Healthcare managed to launch Remsima®® (Inflectra®) in the United States, which is known for having the world’s top pharmaceutical market, and Truxima®, the world's first oncology
mAB biosimilar, in Europe, proving that biosimilars have the potential for success in the global markets.

2015~2017 history image
2015.12
Won the “USD 30 Billion Trade Award” at the
52nd Annual Trade Day
2016.10
The total export value of Remsima® reached
KRW 1 trillion
2016.12
Launched Remsima®(Inflectra®) in the United States
2017 history image
2017.04
Launched Truxima® in Europe
2017.07
Celltrion Healthcare listed on KOSDAQ
2017.12
The market share of Remsima® bypassed
that of the originator medicine as a
biosimilar for the first time in Europe.

Becoming the world’s leading bio-company The biosimilar market has led the global healthcare industry and been recognized for its financial value and growth
potential. Celltrion Healthcare, which brought success to biosimilars, is now taking a bold step into becoming a direct seller of pharmaceuticals to the world.

2018 history imag
2018.05
Launched Herzuma® in Europe
2019.11
Launched Truxima® in the United States
2019.11
RemsimaSC® is approved by Europe (EMA)
2020.02
Launched RemsimaSC® in Europe
Brazil Herzuma Launching Symposium
2020.03
Launched Herzuma® in the United States